MIRA experienced a massive 150% increase in outstanding shares alongside substantial balance sheet improvements, suggesting a significant equity financing event.
The dramatic jump from 16.8M to 42.0M shares outstanding indicates a major dilutive financing round, which explains the strong cash position growth from $2.8M to $6.3M and the 372% increase in stockholders' equity. While this provides crucial runway for the clinical-stage company, existing shareholders face substantial dilution from the 2.5x increase in share count.
MIRA's financial position strengthened significantly with total assets growing 280% to $11.1M and stockholders' equity surging 372% to $10.4M, driven by what appears to be a major equity raise. Operating performance showed mixed results with R&D expenses declining 48% to $1.7M while net losses increased 33% to -$10.4M, though operating cash flow improved modestly. The substantial balance sheet enhancement provides critical funding for this pre-revenue clinical-stage company, but comes at the cost of massive shareholder dilution with outstanding shares increasing 150%.
Equity base grew 372.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Current assets grew 282.9% — improving short-term liquidity or inventory/receivables build.
Asset base grew 279.5% — expansion through organic growth, acquisitions, or capital deployment.
Cash position surged 124% — strong cash generation or capital raise providing significant financial cushion.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
R&D spending cut 48% — could signal cost discipline or concerning reduction in innovation investment.
Net income declined 33% — review whether driven by operations, interest costs, or non-recurring items.
Operating cash flow grew 16.2% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →